Human Insulin Injection (recombinant DNA origin) - Regular, Human Insulin Injection (recombinant DNA origin) or Novolin R; Lente, Human Insulin Zinc Suspension (recombinant DNA origin) or Novolin L; NPH, Human Insulin Isophane Suspension (recombinant DNA origin) or Novolin N; Buffered Regular Human Insulin Injection (rDNA origin) or Velosulin BR; Actraphane; Protaphane; Actarapid -- Product Record

Insulin, rDNA/Novo

    Nomenclature:
      Insulin, rDNA/Novo [BIO]
      Novolin R [TR in U.S.]
      Actraphane [TR for isophane insulin in Europe]
      Novolin L [TR in U.S.]
      Novolin Lente [TR in U.S.]
      Protaphane [TR for protamine insulin in Europe]
      Velosulin BR [TR for buffered solution]
      Novolin N [TR in U.S.]
      Novolin 70/30 [TR in U.S. for 70%/30% mixture of Novolin N and Novolin L]
      Actarapid [TR in Europe]
      Regular, Human Insulin Injection (recombinant DNA origin) [FDA]
      70% NPH, Lente, Human Insulin Zinc Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin) [FDA]
      Buffered Regular Human Insulin Injection (rDNA origin) [FDA]
      Lente, Human Insulin Zinc Suspension (recombinant DNA origin) [FDA]
      NPH, Human Insulin Isophane Suspension (recombinant DNA origin) [FDA]
      Insulin Human [USAN INN BAN for uncomplexed protein]
      11061-68-0 [CAS RN]
      9004-10-8 [CAS RN]
      Human Insulin (Neutral Protamine Hagedorn) [SY for NPH]
      Human Insulin (NPH) [SY]

    molecular weight (kDa) = 5.8 [51 a.a. polypeptide]

    FDA Class:  Drug NDA

    Year of approval (FDA) = 1983